Inflammatory burden and amino acid metabolism in cancer cachexia

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 12, Issue 1, 2009, Pages 72-77

  Durham, William J ^a   Dillon, Edgar Lichar ^a   Sheffield Moore, Melinda ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Amino acid; Ubiquitin proteasome pathway

Indexed keywords

AMINO ACID; GHRELIN; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MELANOCORTIN; MUSCLE PROTEIN; PROTEIN KINASE R; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID METABOLISM; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; APPETITE; CACHEXIA; CANCER CACHEXIA; CLINICAL FEATURE; CYTOKINE PRODUCTION; DIETARY INTAKE; EXPERIMENTAL MODEL; HUMAN; HYPOTHALAMUS; INFLAMMATION; INSULIN TREATMENT; MUSCLE ATROPHY; NONHUMAN; OVARY CANCER; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; WEIGHT REDUCTION;

AMINO ACIDS; ANTI-INFLAMMATORY AGENTS; APPETITE; CACHEXIA; HUMANS; INFLAMMATION; INSULIN; MUSCLE PROTEINS; NEOPLASMS; TESTOSTERONE;

ANIMALIA;

EID: 58149136164     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32831cef61     Document Type: Review

References (45)

1. Tan HL, Fearon KCH. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 2008; 11:400-407. The study places cancer cachexia in its context within the broad category of cachexia.
2. Morley JE, Thomas DR, Wilson M-MG. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006; 84:735-743.
3. Fearon KC, Voss AC, Hustead DS, for the Cancer Cachexia Study Group. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 2006; 83:1345-1350.
4. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet 2003; 362:640-650.
5. Skipworth RJE, Stewart GD, Dejong CHC, et al. Pathophysiology of cancer cachexia: much more than host-tumor interaction? Clin Nutr 2007; 26:667-676. Provides good description and discussion of the acute-phase response elicited in cancer cachexia.
6. Stewart GD, Skipworth RJE, Fearon KCH. Cancer cachexia and fatigue. Clin Med 2006; 6:140-143.
7. Fearon KC. The Sir David Cuthbertson Medal Lecture 1991 : the mechanisms and treatment of weight loss in cancer. Proc Nutr Soc 1992; 51:251-265.
8. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002; 2:862-871.
9. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-545.
10. Acharyya S, Guttridge DC. Cancer signaling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res 2007; 13:1356-1361. Discussion of recent advances in understanding of the signaling pathways implicated in cancer cachexia, particularly evidence for a role of the ubiquitin proteasome pathway.
11. DeBoer MD. Melanocortin interventions in cachexia: how soon from bench to bedside? Curr Opin Clin Nutr Metab Care 2007; 10:457-462. Excellent review of the role of the melanocortin system in cachexia. Includes discussion of therapeutic approaches.
12. Garcia JM, Garcia-Touza M, Hijazi RA, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 2005; 90:2920-2926.
13. Shimizu Y, Nagaya N, lsobe T, et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 2003; 9:774-778.
14. Wolf I, Sadetzki S, Kanety H, et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 2006; 106:966-973.
15. van Hall G, Steensburg A, Fischer C, et al. Interleukin-6 markedly decreases skeletal muscle protein turnover and increases nonmuscle amino acid utilization in healthy individuals. J Clin Endocrinol Metab 2008; 93:2851-2858. Human study suggesting that IL-6 reduces muscle protein synthesis. Notably, IL-6 reduced muscle protein breakdown but had profound effect on protein turnover in nonmuscle tissues.
16. McFarlane C, Sharma M, Kambadur R. Myostatin is a procachectic growth factor during postnatal myogenesis. Curr Opin Clin Nutr Metab Care 2008; 11:422-427. Discussion of the possible role of myostatin in muscle protein breakdown, adding a new dimension to our understanding of how this protein regulates muscle mass.
17. Costelli P, Muscaritoli M, Bonetto A, et al. Muscle myostatin signaling is enhanced in experimental cancer cachexia. Eur J Clin Invest 2008; 38:531-538. Evidence of a role for myostatin signaling, possibly initiated by TNF-alpha;, in cancer cachexia.
18. Proud CG. Signaling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem J 2007; 403:217-234. Comprehensive review of the regulation of translation.
19. Lang CH, Frost RA, Vary TC. Regulation of muscle protein synthesis during sepsis and inflammation. Am J Physiol Endocrinol Metab 2007; 293:E453-E459. Concise review including discussion of the effects of inflammatory signaling on translation initiation.
20. Eley HL, Russell ST, Tisdale MJ. Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem J 2007; 407:113-120. Shows efficacy of branched chain amino acids in the face of inflammation in a model of cancer cachexia. Effects on PKR suggest novel mechanism for responses to branched chain amino acids in cancer cachexia.
21. Biolo G, Declan Fleming RY, Wolfe RR. Physiologic hyperinsulinemia stimulates protein synthesis and enhances transport of selected amino acids in human skeletal muscle. J Clin Invest 1995; 95:811-819.
22. Schmitt TL, Martignoni ME, Bachmann J, et al. Activity of the Akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia. J Mol Med 2007; 85:647-654.
23. Eley HL, Tisdale MJ. Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J Biol Chem 2007; 282:7087-7097. Provides a novel mechanistic link between accelerated protein breakdown and inhibited protein synthesis involving PKR.
24. Wu A-L, Kim J-H, Zhang C, et al. Forkhead box protein 01 negatively regulates skeletal myocyte differentiation through degradation of mammalian target of rapamycin pathway components. Endocrinology 2008; 149:1407-1414. Describes a new role for FOXO signaling in skeletal muscle.
25. Stitt TN, Drujan D, Clarke BA, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004; 14:395-403.
26. Dillon EL, Volpi E, Wolfe RR, et al. Amino acid metabolism and inflammatory burden in ovarian cancer patients undergoing intense oncological therapy. Clin Nutr 2007; 26:736-743. Demonstrates efficacy of amino acid supplementation in cancer patients with evidence of marked inflammation. Also suggests that muscle protein breakdown is not elevated in these patients.
27. Lundholm K, Bennegard K, Eden E, et al. Efflux of 3-methylhistidine from the leg in cancer patients who experience weight loss. Cancer Res 1982; 42:4807-4811.
28. Svaninger G, Bennegard K, Ekman L, et al. Lack of evidence for elevated breakdown rate of skeletal muscles in weight-losing, tumor-bearing mice. J Natl Cancer Inst 1983; 71:341-346.
29. McNurlan MA, Heys SD, Park KG, et al. Tumour and host tissue responses to branched-chain amino acid supplementation of patients with cancer. Clin Sci 1994; 86:339-345.
30. Skipworth RJE, Fearon KCH. The scientific rationale for optimizing nutritional support in cancer. Eur J Gastroenterol Hepatol 2007; 19:371-377. Discussion of importance of nutrition in cancer treatment. Also provides partial explanation for divergent results in animal models and humans with cancer.
31. Colomer R, Moreno-Nogueira JM, Garcia-Luna PP, et al. n-3 fatty acids, cancer and cachexia: a systemic review of the literature. Br J Nutr 2007; 97:823-831.
32. Fearon KCH, Barber MD, Moses AG, et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006; 24:3401-3407.
33. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 2005; 8:265-269.
34. Lundholm K, Daneryd P, Korner U, et al. Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 2004; 24:505-512.
35. Lundholm K, Gelin J, Hyltander A, et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994; 54:5602-5606.
36. Drummond MJ, Rasmussen BB. Leucine-enriched nutrients and the regulation of mammalian target of rapamycin signaling and human skeletal muscle protein synthesis. Curr Opin Clin Nutr Metab Care 2008; 11:222-226. Discussion of the role of leucine in skeletal muscle anabolic signaling.
37. Biolo GD, De Cicco M, Dal Mas V, et al. Response of muscle protein and glutamine kinetics to branched-chain enriched amino acids in intensive care patients after radical cancer surgery. Nutrition 2006; 22:475-482.
38. Lundholm K, Korner U, Gunnebo L, et al. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res 2007; 13:2699-2706. Reports that low-dose insulin, when given as part of a combination treatment including anti-inflammatories, improves survival. This insulin treatment regimen does not, however, appear to prevent loss of skeletal muscle.
39. Biolo G, De Cicco M, Lorenzon S, et al. Treating hyperglycemia improves skeletal muscle protein metabolism in cancer patients after major surgery. Crit Care Med 2008; 36:1768-1775. Reports that insulin treatment, given to reduce hyperglycemia, helps preserve muscle in cancer patients during the immediate postsurgery period.
40. Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 2002; 282:E601-E607.
41. Khosla S, Atkinson EJ, Dunstan CR, O'Fallon WM. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 2002; 87:1550-1554.
42. Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004; 89:3313-3318.
43. Yesilova Z, Ozata M, Kocar IH, et al. The effects of gonadotropin treatment on the immunological features of male patients with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2000; 85:66-70.
44. Greenhaff PL, Karagounis LG, Peirce N, et al. Disassociation between the effects of amino acids and insulin on signaling, ubiquitin-ligases and protein turnover in human muscle. Am J Physiol Endocrinol Metab 2008; 295:E595-E604. Suggests that pathways putatively involved in the regulation of skeletal muscle protein metabolism do not always respond to nutritional or hormonal stimuli in accordance with observed responses of muscle protein synthesis and breakdown.
45. Ferrando AA, Tipton KD, Doyle D, et al. Testosterone injection stimulates net protein synthesis but not tissue amino acid transport. Am J Physiol 1998; 275:E864-E871.